Upcoming IPOs for the Week

Monday, March 6th

- Verge Genomics, Inc. (VERGE): A clinical-stage biopharmaceutical company focused on developing and commercializing transformative therapies for patients with serious diseases.

- Kinnate Biopharma Inc. (KNTE): A clinical-stage biopharmaceutical company developing novel antibody therapeutics for patients with cancer and autoimmune diseases.

Tuesday, March 7th

- Protagonist Therapeutics, Inc. (PTGX): A clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapeutics for severe inflammatory and fibrotic diseases.

- Viela Bio, Inc. (VIE): A clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody therapeutics for autoimmune and severe inflammatory diseases.

Wednesday, March 8th

- Alector, Inc. (ALEC): A clinical-stage biopharmaceutical company developing monoclonal antibodies to treat neurodegenerative diseases, including Alzheimer's disease and frontotemporal dementia.

- Ocugen, Inc. (OCGN): A clinical-stage biopharmaceutical company focused on developing gene therapies for inherited retinal diseases and other rare genetic disorders.

Thursday, March 9th

- Mustang Bio, Inc. (MBIO): A clinical-stage biopharmaceutical company focused on the development and commercialization of autologous gene therapies for hematologic malignancies and genetic diseases.

- TFF Pharmaceuticals, Inc. (TFFP): A clinical-stage biopharmaceutical company developing a pipeline of innovative therapies for diseases with high unmet medical needs, including cancer and autoimmune diseases.

Friday, March 10th

- Atreca, Inc. (ATRC): A clinical-stage biopharmaceutical company developing novel antibody-drug conjugate therapies for the treatment of cancer.

- Minerva Neurosciences, Inc. (NERV): A clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of neuropsychiatric diseases.